Medicilon’s Rodent Cerebrovascular Disease Drug Efficacy Evaluation System

서비스분야

Chemistry Services
-- Medicinal Chemistry -- Synthetic Chemistry -- Process Development -- Analytical Chemistry
Drug Formulation
-- Pre-Formulation Development -- Analytical Development -- Formulation Development -- Generics Consistency Evaluation -- Research on Quality Control -- Clinical Trial Material Manufacturing, Packaging & Labeling
Biology Services
-- NanoString nCounter Detection Platform -- Single B Cell antibody discovery technology -- Recombinant Protein Services -- Crystallization & Structural Determination -- Discovery Biology Services -- SeMet Media Sales -- Kinase Services -- Computational Biology & Molecular Modeling
Pharmacology
-- Cancer Xenograft Models -- Orthotopic Models -- Syngeneic models -- Transgenic Mouse Model -- Humanized Mouse Model -- PDX Model -- Digestive System Model -- Metabolic Disease Models -- Inflammation & Immunological Disease Models -- Neurological Disorders Models -- Other Disease Models
Pharmacokinetics
-- In Vitro Assays -- In Vivo Assays
Bioanalytical
-- Large Molecule Services -- Small Molecule Services
Drug Safety Evaluation
-- Basic Information -- Safety Pharmacology Research -- Inhalation toxicity assessment -- ophthalmic drug development
Integrated Projects
-- Rodent Cerebrovascular Disease Drug Efficacy Evaluation System -- Nucleic Acid Drug R&D Platform -- Pharmaceutical Research CDMO Service Platform -- Solid Form Screening Platform -- Non-clinical Research for Cellular Immunotherapies -- Skin Topical Preparation R&D -- Inhalation Formulation R&D Platform -- Preclinical Research Services -- Chemical Compound Druggability Assessment -- Chemical Drug Development -- Bio Drug Development -- Antibody Drug Antibody -- IND Filing

Rodent Cerebrovascular Disease Drug Efficacy Evaluation System

현재 위치：홈 > Services & Solutions > Integrated Projects > Rodent Cerebrovascul...

Cardiovascular and cerebrovascular diseases generally refer to ischemic or hemorrhagic diseases of the heart, brain and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, and hypertension.

Range of Cerebrovascular Disease

Disease	ICD 10	Models
Intracerebral hemorrhage	I60-I62	Intracranial Autologous Blood Injection，Subarachnoid hemorrhage
Cerebral infarction	I63	Ischemic stroke model
Stroke	I64
Cerebral thrombosis	I65
Cerebral Embolism	I66
Other	I67-I69	Other

The annual treatment cost of cardiovascular and cerebrovascular diseases in China is RMB 540.6 billion. The annual treatment cost of cerebrovascular diseases accounts for 25.68% of cardiovascular and cerebrovascular diseases. Among them, ischemic stroke accounts for 18% and hemorrhagic stroke accounts for 7%.

cardiovascular and cerebrovascular diseases models

Advantages of Medicilon MCAO Model Evaluation System

• Rat and mouse MCAO models with stable lesions, high success rate and high survival rate

• Reliable and effective evaluation of dose-effect/time-effect relationship

• Efficacy evaluation of transient cerebral ischemia and permanent cerebral ischemia

• Complete the investigation of various pharmacodynamic core indicators according to STAIR technical guidelines

• The model rodents could be customized with special diseases and complete activity evaluations according to customer requirements

MCAO Mouse Model Evaluation System - Investigation of Dose-Response and Time-Response Relationship

Animals: ICR mice, male

Group: Control Group, Model Group, Positive Drug Group (Xianbixin)

Methodology:

• The right middle artery of the mice was blocked by suture method, and the suture was removed after blocking for 1 h to achieve reperfusion.

• Dose-Response Investigation: Animals were given the positive drug Xianbisxin 20, 10, 1, 0.1 and 0.01 mg/kg intravenously at 0.5h after infarction, respectively, and the dose-effect relationship was investigated.

• Time-Response Investigation: Animals were given the positive drug Xianbixin 20mg/kg intravenously at 0.5h after infarction and 2h, 6h, 8h and 10h after reperfusion respectively, and the time-effect relationship was investigated.

Inspection indicators

The infarct volume was measured by TTC method, and the brain water content was measured by drying method.

Evaluation of the MCAO Mouse Model - Dose-Response Relationship

Dose-Effect Relationship Study (TTC and brain water content) (mean±SEM)

Evaluation of the MCAO Mouse Model - Time-Response Relationship

Time-Effect Relationship Study (TTC and brain water content) (mean±SEM)

MCAO Mouse Model Evaluation System - Trement Time Window Investigation

Animals: ICR mice, male

Group: Control Group, Model Group, Positive Drug Group (Xianbixin)

Methodology:

• The right middle artery of the mice was blocked by suture method, and the suture was removed after 1h, 2h and 4h of blocking to achieve reperfusion.

• Treatment Time Window Investigation: Animals were intravenously injected with the positive drug Xianbixin 20mg/kg 0.5h after infarction, and the treatment time window was investigated.

Inspection indicators

Infarct volume was measured by TTC method, brain volume by drainage method, and brain water content by drying method.

Result

Treatment Time Window Investigation A: TTC; B: Brain Volume, C: Brain Water Content (mean±SEM)

Treatment Time Window Investigation

MCAO Mouse Model Evaluation System - Neurological Recovery Investigation

Animals: ICR mice, male

Group: Control Group, Model Group, Positive Drug Group (Xianbixin)

Methodology:

• The right middle artery of the mice was blocked by suture method, and the suture was removed after blocking for 1 h to achieve reperfusion.

• Neurological Recovery Investigation: Animals were intravenously injected with the positive drug Xianbixin 20mg/kg 0.5h after infarction, and the treatment time window was investigated.

Inspection indicators

Zea-longa score, Balance Beam Transit Time, Rotarod Dwell Time, Grip Strength

MCAO Mouse Model Evaluation System-Investigation of Neurological Function

Pharmacodynamic Investigation of Neurological Function: A: Zea-longa score; B: Balance Beam Transit Time

Pharmacodynamic Investigation of Neurological Function

Pharmacodynamic Investigation of Neurological Function: C: Rotarod Dwell Time; D: Grip Strength

Pharmacodynamic Investigation of Neurological Function

MCAO Rat Model Evaluation System

Animals: SD Rat, male

Group: Control Group, Model Group, Positive Drug Group 1 (Edaravone), Positive Drug Group 2 (Nimodipine)

Methodology:

• The right middle artery of the mice was blocked by suture method, and the suture was removed after blocking for 2h to achieve reperfusion.

• Pharmacodynamics Study: Animals were given the positive drugs by intravenous injection at 0.5h after infarction, and the pharmacodynamic effects of the two positive drugs were investigated.

Inspection indicators

Zea-longa score, Infarct Volume by TTC method

Result-1: Behavioral Scores of Rats

Behavioral Scores of Rats

Rat Behavioural Examination (Zea-longa Score and Animal Behaviour)

Rat Behavioural Examination (Zea-longa Score and Animal Behaviour)

Result-2：TTC Staining of Brain

Cerebral Infarction Volume Investigation (TTC staining and infarct volume ratio)